ANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB)

The goal of the study is to develop predictive algorithms and digital biomarkers to capture disease fluctuations in (prodromal) dementia with lewybodies (DLB) patients and to improve treatment, diagnosis and prognosis of the study drug Ambroxol, used in the ANeED study. This project is an additional study to the ANeED study, registered at ClinicalTrials.gov under NCT04588285.

NCT Number	NCT05773443
Lead Sponsor	University of Bergen Collaborators: Helse Fonna, Helse Stavanger HF, University Hospital, Akershus, Ullevaal University Hospital, Haraldsplass Deaconess Hospital, St. Olavs Hospital
Conditions	Dementia, Lewy Body
Enrollment	100 participants
Start Date	2023-03
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2023-03-17